commercially available in the United States for over a decade. The first tests were cleared by the US 23
Food and Drug Administration (FDA) in enzyme-linked immunosorbent assay (ELISA) format, with a rapid 24 immunochromatographic assay (ICA) format gaining FDA clearance in 2009. These assays allow 25 laboratories to significantly shorten the turn-around-time (TAT) for Campylobacter detection from 26 greater than 72 hours to less than 24 hours; or in the case of ICA tests, less than an hour. The rapidity of 27 which test results are available has potential significance for clinical microbiology laboratories that are 28 under growing pressure to provide more rapid test results, with less available workforce; these tests 29 however must generate clinically meaningful results. A significant challenge with Campylobacter stool 30 antigen CIDTs has been the lack of consistent results in published studies. While some studies have 31 described excellent sensitivity and specificity versus conventional Campylobacter culture, sometimes 32 with enhanced sensitivity compared to culture (5, 6), others have reported poor specificity and variable 33 sensitivity (7-10). Still others have shown that these assays potentially have broader detection within 34 the Campylobacter genus than what the manufacturers have indicated in their instructions for use 35 (further complicating the true analytical performance) (9-12). This collective body of work has 36 culminated into a quagmire of conflicting/inconsistent data and even contentious opinions as to the 37 best use of these assays (if any) for clinical care in the diagnosis and reporting of campylobacteriosis. 38
Currently the public health reporting criteria for a confirmed case of campylobacteriosis is contingent 39 upon recovery of an isolate from stool culture; with CIDTs only serving as supportive evidence for a 40 probable case (http://wwwn.cdc.gov/nndss/conditions/campylobacteriosis/case-definition/2015/). 41
With increasing adoption of CIDTs for Campylobacter there are lingering concerns as to how these 42 results will be used in the clinical microbiology laboratory, whether isolates will cease to be provided for 43 public health investigations due to cessation of culture, whether the lack of inclusion of CIDTs in the case 44 definition will result in decreased case reporting, and most importantly whether the stool antigen The second major finding and the primary focus of this study was demonstrating that stool 69 antigen CIDTs have highly variable sensitivity, specificity, and positive predictive value (PPV) in a low 70 prevalence setting when mCCDA and Campy CVA combination culture is used as the reference culture 71 method. True cases in this study were defined based on specific laboratory test combinations including 72 any culture positive or positive by a single stool antigen CIDT and PCR. Non-cases were defined as 73 illnesses in which specimens were positive by only stool antigen tests or PCR but not both. Using these 74 definitions, of 202 non-cases that were positive by at least one CIDT, only one sample was positive by all 75 four stool antigen CIDTs and PCR, but negative by culture. Furthermore, 75% of these non-cases were 76 positive by only one CIDT and negative by all other methods (antigen tests, cultures, and PCR), 77 suggesting very poor analytical specificity for the stool antigen CIDTs. These cases were further qualified 78 by the fact that non-cases were less likely to have clinically compatible symptoms to support a diagnosis 79 of campylobacteriosis, also calling into question the clinical specificity of these assays. 80
Taken together, despite reasonably high specificity (greater than 95%), the positive predictive 81 value of three of the stool antigen CIDTs ranged only from 36-51% (slightly better than a flip of a coin, at 82 best), while the negative predictive values (NPV) all exceeded 99% as would be expected in such low 83 prevalence settings. The assay with the lowest PPV was an ICA assay, which is ironically the assay with 84 the broadest superficial appeal to clinical microbiology laboratories (rapid TAT, no sample batching, 85 simple to perform) particularly when compared to an ELISA. 86
Though cross-reactivity with other Campylobacter species has been reported for stool antigen 87
CIDTs previously, the authors did not investigate this aspect of the analytical specificity of the assays (9-88 12). Nonetheless it is important to consider that "non-cases" were typically not clinically compatible 89 antigen CIDTs do not perform adequately to serve as a stand-alone diagnostic tool for 94 campylobacteriosis, a valid conclusion which echoes other investigators in Europe (7). 95 This is an important conclusion that deserves discussion since these data would not support the 96 laboratory practice of replacing Campylobacter culture with stool antigen CIDTs entirely. Laboratories 97 that have adopted stool antigen CIDTs as their sole detection tool for Campylobacter spp. should revisit 98 this practice in their institution in light of these data. One approach for laboratories that are intent on 99 reducing time-consuming, low-yield Campylobacter cultures may be instead to consider screening with 100 stool antigen CIDTs, and reflexing only the positives to culture as has been advocated previously (7) . 101
This approach is not without significant limitation; despite the high NPV, the sensitivity of the stool 102 antigen CIDTs versus both culture and case definition were below 90% in this study, meaning even in a 103 low prevalence setting, some Campylobacter-positive specimens will not be detected. These overall 104 troubling test characteristics paired with growing institutional pressures to reduce TAT and perform 105 more testing with fewer employees leads to significant confusion and uncertainty for clinical 106 laboratories in determining the most appropriate choice for testing for Campylobacter. 107 
